Santen Pharmaceutical Co., Ltd. provided consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27. On IFRS basis, the company expects revenue of ¥273,000 million, operating profit of ¥32,000 million, net profit for the year of ¥22,400 million and basic earnings per share of ¥61.24.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,614 JPY | -0.28% | +5.66% | +14.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.91% | 3.75B | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.28% | 238B | |
+7.22% | 204B | |
-6.13% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- 4536 Stock
- News Santen Pharmaceutical Co., Ltd.
- Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024